Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.